United States
Print page content Print
Increase text size Decrease text size
Text Size

ARVAC®

Equine ARTERITIS vaccine

ARVAC

ARVAC® aids in the prevention of viral abortion and respiratory infection due to equine arteritis virus.

Equine arteritis virus is a contagious equine disease with an increasing number of cases.1 Although rarely life-threatening in healthy adult horses, equine arteritis virus can cause pregnant mares to abort and death in young foals, and breeding stallions can become long-term disease carriers.1 The equine abortion rate due to equine arteritis virus can be as high as 50% to 60%.2

Collapse All
    • Aids in the prevention of viral abortion and respiratory infection due to equine arteritis virus for healthy nonstressed adult horses.
    • Contains a modified-live equine arteritis virus.
    • Aseptically rehydrate to liquid form using the diluent supplied, and administer one 1-mL dose intramuscularly.
      • Annual booster dose is recommended.
    • Vaccinate males and young animals at any time, but stallions should be vaccinated not less than three weeks prior to breeding.
    • Vaccinate mares preferably as maidens or when open.
      • Maiden or barren mares may be vaccinated at any time, but should be vaccinated not less than three weeks prior to breeding.
      • Mares in-foal should not be vaccinated until after foaling and then not less than three weeks prior to breeding.
    • In case of anaphylactoid reaction, administer epinephrine.

    Packaging

    • Ten 1 mL vials of vaccine and ten 1 mL vials of diluent

    CAUTIONS

    • Store in the dark at 2° to 7°C (35° to 45°F). Use entire contents within 60 minutes after rehydration.
    • Burn container and unused contents.
    • In case of anaphylactoid reaction, administer epinephrine.
    • Do not vaccinate within 21 days before slaughter.
    • The vaccinal virus has been modified to the extent that it may be irregularly infective when given by natural portals of entry. A high degree of safety has been demonstrated for horses of any age and pregnant mares. However, the vaccination of foals under 6 weeks of age is not recommended except in emergency situations when threatened by natural exposure.
    • Pregnant mares SHOULD NOT be vaccinated during the last two months of gestation since a few instances of fetal invasion by vaccinal virus have been demonstrated during this period. It is preferable to immunize mares during the maiden or open periods; however, when pregnant mares are threatened by known natural exposure, vaccination may be undertaken with considerably less risk than is inherent in natural infection. Owners are to be advised of the possibility of fetal infection before vaccinating pregnant mares.
    • Mild post-vaccinal febrile reactions and normal total white counts with mild transient lymphopenia have occurred in some vaccinates. Vaccinated horses will serologically convert, a condition that should be kept in mind in the case of animals intended for export to countries with regulations regarding EAV.
    • Distribution shall be limited to those states where authorized by proper state officials and under such additional conditions as these authorities may require.

EQB-00018